Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kleen Enema is a saline osmotic laxative developed and manufactured by Nabiqasim Industries (Pvt) Ltd. It is primarily indicated for rapid bowel preparation prior to diagnostic procedures such as sigmoidoscopy, colonoscopy, or surgery, and for the relief of occasional constipation. The formulation consists of a concentrated solution of monobasic sodium phosphate and dibasic sodium phosphate. When administered rectally, these inorganic salts create a high osmotic gradient that draws water from the surrounding extracellular fluid into the intestinal lumen. This increase in fluid volume softens the stool and distends the colon, which triggers peristaltic contractions and facilitates rapid evacuation of the lower bowel, typically within 2 to 5 minutes. A Phase 4 clinical study has specifically evaluated the efficacy and safety of Kleen Enema for bowel preparation in outpatients undergoing sigmoidoscopy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kleen Enema.